The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey

Bocchetta, Martina and Galluzzi, Samantha and Kehoe, Patrick Gavin and Aguera, Eduardo and Bernabei, Roberto and Bullock, Roger and Ceccaldi, Mathieu and Dartigues, Jean-François and de Mendonça, Alexandre and Didic, Mira and Eriksdotter, Maria and Félician, Olivier and Frölich, Lutz and Gertz, Hermann-Josef and Hallikainen, Merja and Hasselbalch, Steen G. and Hausner, Lucrezia and Heuser, Isabell and Jessen, Frank and Jones, Roy W. and Kurz, Alexander and Lawlor, Brian and Lleo, Alberto and Martinez-Lage, Pablo and Mecocci, Patrizia and Mehrabian, Shima and Monsch, Andreas and Nobili, Flavio and Nordberg, Agneta and Rikkert, Marcel Olde and Orgogozo, Jean-Marc and Pasquier, Florence and Peters, Oliver and Salmon, Eric and Sánchez-Castellano, Carmen and Santana, Isabel and Sarazin, Marie and Traykov, Latchezar and Tsolaki, Magda and Visser, Pieter Jelle and Wallin, Åsa K. and Wilcock, Gordon and Wilkinson, David and Wolf, Henrike and Yener, Görsev and Zekry, Dina and Frisoni, Giovanni B.. (2015) The use of biomarkers for the etiologic diagnosis of MCI in Europe: an EADC survey. Alzheimer's & dementia : the journal of the Alzheimer's Association, 11 (2). pp. 195-206.e1.

PDF - Accepted Version
Available under License CC BY-NC-ND (Attribution-NonCommercial-NoDerivatives).
1285Kb

Official URL: http://edoc.unibas.ch/41181/

Downloads: Statistics Overview

Abstract

We investigated the use of Alzheimer's disease (AD) biomarkers in European Alzheimer's Disease Consortium centers and assessed their perceived usefulness for the etiologic diagnosis of mild cognitive impairment (MCI). We surveyed availability, frequency of use, and confidence in diagnostic usefulness of markers of brain amyloidosis (amyloid positron emission tomography [PET], cerebrospinal fluid [CSF] Aβ42) and neurodegeneration (medial temporal atrophy [MTA] on MR, fluorodeoxyglucose positron emission tomography [FDG-PET], CSF tau). The most frequently used biomarker is visually rated MTA (75% of the 37 responders reported using it "always/frequently") followed by CSF markers (22%), FDG-PET (16%), and amyloid-PET (3%). Only 45% of responders perceive MTA as contributing to diagnostic confidence, where the contribution was rated as "moderate". Seventy-nine percent of responders felt "very/extremely" comfortable delivering a diagnosis of MCI due to AD when both amyloid and neuronal injury biomarkers were abnormal (P < .02 versus any individual biomarker). Responders largely agreed that a combination of amyloidosis and neuronal injury biomarkers was a strongly indicative AD signature.

Faculties and Departments:	03 Faculty of Medicine > Bereich Medizinische Fächer (Klinik) > Geriatrie > Geriatrie (Kressig) 03 Faculty of Medicine > Departement Klinische Forschung > Bereich Medizinische Fächer (Klinik) > Geriatrie > Geriatrie (Kressig) 07 Faculty of Psychology > Departement Psychologie
UniBasel Contributors:	Monsch, Andreas U
Item Type:	Article, refereed
Article Subtype:	Research Article
Publisher:	Elsevier
ISSN:	1552-5279
Note:	Publication type according to Uni Basel Research Database: Journal article
Language:	English
Identification Number:	doi: 10.1016/j.jalz.2014.06.006 pmid: 25150733
edoc DOI:	10.5451/unibas-ep41181
Last Modified:	15 Nov 2016 15:08
Deposited On:	14 Jul 2016 09:08

Repository Staff Only: item control page